Sprint Bioscience AB (OSTO:SPRINT) PE Ratio without NRI: 5.21 (As of Jul. 03, 2026) — 68% Below Median


OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr4.06
GF Value kr2.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sprint Bioscience AB PE Ratio without NRI?

Sprint Bioscience AB OSTO:SPRINT -4.92% 32 PE Ratio without NRI is 5.21 as of Jul. 03, 2026, which is 68% below its 10-year median of 16.27. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 267 Biotechnology companies, Sprint Bioscience AB ranks better than 89.89% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-03), Sprint Bioscience AB's share price is kr4.06. Sprint Bioscience AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.78. Therefore, Sprint Bioscience AB's PE Ratio without NRI for today is 5.21.

During the past 13 years, Sprint Bioscience AB's highest PE Ratio without NRI was 50.58. The lowest was 1.80. And the median was 16.27.

Sprint Bioscience AB's EPS without NRI for the three months ended in Mar. 2026 was kr-0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.78.

As of today (2026-07-03), Sprint Bioscience AB's share price is kr4.06. Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.78. Therefore, Sprint Bioscience AB's PE Ratio (TTM) for today is 5.21.

Warning Sign:

Sprint Bioscience AB stock PE Ratio (=5.71) is close to 1-year high of 5.71.

During the past years, Sprint Bioscience AB's highest PE Ratio (TTM) was 50.58. The lowest was 1.80. And the median was 16.27.

Sprint Bioscience AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.78.

Sprint Bioscience AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.79.


Sprint Bioscience AB  (OSTO:SPRINT) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Sprint Bioscience AB PE Ratio without NRI Related Terms


Sprint Bioscience AB PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB PE Ratio without NRI Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss N/A At Loss At Loss 1.50

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss 1.50 3.05

OSTO:SPRINT vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's PE Ratio without NRI falls into.


OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Sprint Bioscience AB's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=4.06/0.780
=5.21

Sprint Bioscience AB's Share Price of today is kr4.06.
Sprint Bioscience AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.78.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 5.21 mean?
Sprint Bioscience AB (OSTO:SPRINT) has a PE Ratio without NRI of 5.21 as of Jul. 03, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sprint Bioscience AB and its competitors. This is 68% below median its historical median of 16.27. Over the past decade, Sprint Bioscience AB's PE Ratio without NRI has ranged from 1.80 to 50.58. According to the industry distribution chart, Sprint Bioscience AB ranks #27 out of 267 companies in the Biotechnology industry, placing it in the top 10.1%.
Is Sprint Bioscience AB's PE Ratio without NRI too high?
Sprint Bioscience AB's current PE Ratio without NRI of 5.21 is 68% below median its 10-year median of 16.27. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 50.58. The Biotechnology industry median PE Ratio without NRI is 25.64. Sprint Bioscience AB's value of 5.21 is 79.7% below this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #27 out of 267 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #27 out of 267 companies for PE Ratio without NRI. This places Sprint Bioscience AB in the top 10% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 25.64. Sprint Bioscience AB's value of 5.21 is 79.7% below this benchmark. Historically, Sprint Bioscience AB's own PE Ratio without NRI has ranged from 1.80 to 50.58 over the past decade. While the company's 10-year median is 16.27 vs. the industry median of 25.64, Sprint Bioscience AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.64, based on 267 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current PE Ratio without NRI of 5.21 is 79.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current PE Ratio without NRI is 5.21, which is 68% below median its own 10-year median of 16.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current PE Ratio without NRI is 5.21, which is 68% below median its 10-year median of 16.27 and 79.7% below the Biotechnology industry median of 25.64. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current PE Ratio without NRI is 5.21 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • PE Ratio without NRI: 5.21 (68% below median its 10-year median of 16.27)
  • GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
  • GF Score™: 32/100 with 4 warning signs
  • Industry Position: 79.7% below the Biotechnology median (#27 of 267)

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.06
Price
kr2.18
GF Value